Lung Cancer
Conditions
Keywords
stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage IIIA non-small cell lung cancer
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Detailed description
OBJECTIVES: * Compare survival of patients with previously untreated stage IB, II, or selected IIIA non-small cell lung cancer after preoperative chemotherapy comprising paclitaxel and carboplatin plus surgery vs surgery alone. * Compare these regimens in terms of operative mortality and other toxic effects in these patients. * Evaluate the response rates (confirmed and unconfirmed) and toxic effects associated with combined paclitaxel and carboplatin in these patients. * Obtain samples for correlation of radiologic, pathologic, molecular, and biologic factors with the outcome in patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to clinical stage (IB or IIA vs IIB or IIIA). Patients are randomized to one of two treatment arms: * Arm I: Patients undergo thoracotomy. All accessible hilar (level 10) lymph nodes are dissected, and complete mediastinal lymph node sampling is performed. * Arm II: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of course 3, patients undergo thoracotomy and lymph node dissection as in arm I. Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually until year 10. PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 4 years.
Interventions
DRUGcarboplatin
DRUGpaclitaxel
PROCEDUREconventional surgery
Sponsors
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
North Central Cancer Treatment Group
Radiation Therapy Oncology Group
SWOG Cancer Research Network
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically proven non-small cell lung cancer (NSCLC), meeting 1 of the following staging criteria: * Stage IB (T2, N0) * Stage II * T1-2, N1 with negative mediastinoscopy OR * T3, N0 * Selected stage IIIA with negative mediastinoscopies * T3, N1, excluding superior sulcus * Positive level 10 hilar nodes allowed if mediastinoscopy negative * Apical tumors with no clinical symptoms allowed * No symptomatic tumors (T3, N0 or T3, N1) involving the superior sulcus * No Pancoast's tumors * Negative mediastinoscopy required in all patients with clinically positive mediastinal or hilar lymph nodes to ensure no N2 disease * Bidimensionally measurable or evaluable disease by chest x-ray or contrast-enhanced CT scan * T3, N0 disease assessable only by bronchoscopy must be affirmed by 2 observers and documented by photograph that includes main carina PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0 or 1 Life expectancy: * Not specified Hematopoietic: * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * WBC at least 4,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT or SGPT no greater than 2 times ULN * Alkaline phosphatase no greater than 2 times ULN Renal: * Creatinine no greater than 1.5 times ULN * Creatinine clearance at least 50 mL/min Pulmonary: * See Disease Characteristics * Preresection FEV\_1 greater than 2.0 L OR * Predicted postresection FEV\_1 greater than 1.0 L * No postobstructive pneumonia Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No serious infection * No other serious medical condition that would preclude study compliance * No prior allergic reactions to drugs containing Cremophor * No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior systemic chemotherapy for NSCLC * No other concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * No prior systemic radiotherapy for NSCLC * No concurrent radiotherapy Surgery: * At least 5 years since prior resection of lung disease Other: * No other concurrent investigational therapy * No other concurrent anticancer therapy
Countries
Canada, United States
Outcome results
None listed